UAE raises drug penalties to AED 50,000 fines and 5-year prison terms for controlled substance violations

The UAE has raised penalties for drug-related offences to fines of up to AED 50,000 and prison sentences of up to five years under amendments to Federal Decree-Law No. 30 of 2021 on Combating Narcotics and Psychotropic Substances.

The amended law governs the manufacture, import, export, possession, and distribution of controlled substances across all seven emirates. For healthcare operators, the changes create direct exposure in controlled substance management, pharmacy dispensing protocols, and institutional compliance programs. The previous penalty structure carried lower financial thresholds for several categories of offences, and the new text expands the activities that trigger criminal liability, particularly around facilitation, negligent handling, and failure to report.

Who faces the most immediate risk

Healthcare facilities licensed by the Dubai Health Authority (DHA), the Department of Health Abu Dhabi (DOH), and the Ministry of Health and Prevention (MOHAP) carry the heaviest operational burden. Dubai alone has more than 4,200 licensed healthcare facilities, many of which dispense opioid analgesics, benzodiazepines, and other scheduled substances daily. Abu Dhabi's DOH oversees approximately 3,800 licensed facilities with similar obligations.

Any lapse in record-keeping, dispensing logs, or storage security for Schedule I through IV substances could expose both the institution and individual practitioners to criminal prosecution under the amended provisions. Pharmacy directors and chief pharmacists carry personal liability under UAE narcotics law. A dispensing error, an incomplete audit trail, or a stock discrepancy in controlled substances could result in individual criminal charges carrying the new AED 50,000 fine ceiling.

Private hospital groups operating across multiple emirates face a compounded compliance burden. Each emirate's health authority conducts its own inspections, and the federal law applies uniformly. A facility that passes DHA inspection in Dubai is not exempt from MOHAP scrutiny if it also operates in Sharjah or Ajman.

Four steps operators should take now

• Conduct a full audit of controlled substance inventory, dispensing records, and wastage logs across all facilities
• Review pharmacy staff training on the amended penalty structure and confirm all personnel with controlled substance access have completed updated compliance modules
• Verify that electronic health record systems generate the audit trails required under MOHAP's pharmaceutical inspection standards
• Engage legal counsel to assess institutional exposure under the amended law, particularly for multi-emirate operators

Financial risk beyond the fines

For CFOs, the exposure extends past the AED 50,000 penalty cap. A criminal investigation into controlled substance handling can trigger license suspension reviews by the relevant health authority, which disrupts revenue at the facility level. Insurance coverage for regulatory defence costs varies widely among UAE healthcare policies, and most D&O policies exclude criminal proceedings.

The UAE's narcotics enforcement framework has grown stricter since 2021, when that year's decree-law replaced a 1995 statute and introduced rehabilitation-first pathways for personal use cases while hardening penalties for commercial and institutional violations. The latest amendments continue that trajectory. Regulators now treat institutional compliance failures with the same severity as individual offences.

Hospital COOs should audit their controlled substance chains now: procurement records, dispensing logs, wastage documentation, and access controls for medication storage. The gap between current internal protocols and the new penalty thresholds is where institutional risk sits.